Sofosbuvir + Velpatasvir interactions
Checked as Sofosbuvir + Velpatasvir in this data source.
Full monograph for Sofosbuvir + VelpatasvirCheck it against another medicine
Medicines
143 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloridevia Sofosbuvir | Major | Others | Severe, life-threatening, symptomatic bradycardia has been reported during coadministration of amiodarone with ledipasvir-sofosbuvir or with sofosbuvir taken… | 8 sources — open the full entry |
| Apalutamidevia Velpatasvir, Sofosbuvir | Major | Absorption · Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to…2 documented mechanisms | 14 sources — open the full entry |
| Bosentan Monohydratevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasonevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Carbamazepinevia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Cenobamatevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasonevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Colchicinevia Velpatasvir | Major | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced…2 documented mechanisms | 107 sources — open the full entry |
| Dexamethasonevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicolvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexamethasone + Levofloxacinvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acidvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphatevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexamethasone + Tobramycinvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Dexlansoprazolevia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Efavirenzvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Enzalutamidevia Sofosbuvir, Velpatasvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 14 sources — open the full entry |
| EsomeprazolebaseMUPS preparationvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycinvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Fosphenytoin Sodiumvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Gatifloxacin + Dexamethasonevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapinevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Lansoprazolevia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycinvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Lorlatinibvia Velpatasvir, Sofosbuvir | Major | Absorption · Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to…2 documented mechanisms | 14 sources — open the full entry |
| Morphine Sulfatevia Velpatasvir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasonevia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Naproxen Sodium + Esomeprazole Magnesiumvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| OmeprazolebaseMUPS tabletvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Oxcarbazepinevia Sofosbuvir | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Pantoprazole Sodiumvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Phenobarbitalvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Phenytoin Sodiumvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Primidonevia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycinvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Rabeprazole Sodiumvia Velpatasvir | Major | Absorption | Coadministration of velpatasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 4 sources — open the full entry |
| Relugolixvia Velpatasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…2 documented mechanisms | 3 sources — open the full entry |
| Relugolix + Estradiol + Norethindronevia Velpatasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…2 documented mechanisms | 3 sources — open the full entry |
| Rifampicinvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazidvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutolvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rosuvastatin + Ezetimibevia Velpatasvir | Major | Distribution · Metabolism | Coadministration with velpatasvir may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is velpatasvir inhibition of the…2 documented mechanisms | 2 sources — open the full entry |
| Rosuvastatin Calciumvia Velpatasvir | Major | Distribution · Metabolism | Coadministration with velpatasvir may significantly increase the plasma concentrations of rosuvastatin. The proposed mechanism is velpatasvir inhibition of the…2 documented mechanisms | 2 sources — open the full entry |
| Sotorasibvia Velpatasvir | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to… | 3 sources — open the full entry |
| Abametapirvia Velpatasvir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450…2 documented mechanisms | 2 sources — open the full entry |
| Abiraterone Acetatevia Velpatasvir | Moderate | Metabolism | Coadministration with abiraterone acetate may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C8. Abiraterone is a potent…2 documented mechanisms | 7 sources — open the full entry |
| Acarbosevia Sofosbuvir, Velpatasvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Afatinib Dimaleatevia Velpatasvir | Moderate | Distribution · Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter.2 documented mechanisms | 5 sources — open the full entry |
| Alogliptin Benzoatevia Sofosbuvir, Velpatasvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Velpatasvir | Moderate | Absorption | INTERVAL: Concurrent administration of velpatasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Velpatasvir…4 documented mechanisms | 2 sources — open the full entry |
Conditions
Conditions in which Sofosbuvir + Velpatasvir needs care, as documented in this source.
IMMUNE SUPPRESSION
MajorHBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive). HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients. All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy. Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.
7 sources
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
- "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences (2014):
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
- "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
- "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences (2016):
- "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences (2017):
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical (2017):
Hepatic Insufficiency
ModerateSofosbuvir is extensively metabolized in the liver. The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis. No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
Kidney Diseases
ModerateThe safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis. No dosage recommendation can be given for patients with severe renal impairment or ESRD. No dosage adjustment is necessary for patients with mild or moderate renal impairment.
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):